Fig. 1From: Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trialsMaintenance of treatment response in Weeks 13–24 based on the migraine response rate in Weeks 1–12 in PROMISE-1 and PROMISE-2 (pooled): (A) Percentage of eptinezumab-treated patients maintaining ≥ 75% or ≥ 50–< 75% migraine response during the first infusion (Weeks 1–12) and (B) Percentage of eptinezumab-treated patients maintaining ≥ 50–< 75% migraine response maintaining response in Weeks 13–24Back to article page